Management of Cerebral Venous Sinus Thrombosis: UK Guidelines Summary
Immediate Anticoagulation
Start therapeutic anticoagulation immediately upon diagnosis with low-molecular-weight heparin (LMWH), even in the presence of intracranial hemorrhage, unless absolute contraindications exist. 1
- LMWH is preferred over unfractionated heparin for the first 5-10 days of acute treatment 1, 2
- Subcutaneous LMWH should be initiated at the time of diagnosis 1
- Intravenous unfractionated heparin may be used when subcutaneous absorption is uncertain or when subsequent thrombolytic therapy is being considered 1
- Hemorrhagic venous infarction is NOT a contraindication to anticoagulation—the hemorrhage results from venous congestion and will worsen without treatment 1, 2, 3
Absolute Contraindications to Anticoagulation
The only true contraindications include: 1
- Active intracranial bleeding unrelated to CVST
- Recent neurosurgical procedures
- Severe thrombocytopenia (platelet count < 50 × 10⁹/L)
- Pre-existing coagulopathy
In these cases, consider inferior vena cava filter placement and/or endovascular therapy as alternatives 1
Long-Term Anticoagulation Strategy
Agent Selection
Direct oral anticoagulants (DOACs) are now recommended over vitamin K antagonists (VKAs) for maintenance therapy after the acute phase. 1
- If DOACs cannot be used, warfarin targeting INR 2.0-3.0 remains acceptable 1
- For cancer-associated CVST, oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are preferred over LMWH 1
- In gastrointestinal malignancy specifically, apixaban or LMWH is favored due to lower bleeding risk 1
Duration of Anticoagulation
The duration depends on the underlying etiology: 1
| Clinical Scenario | Duration |
|---|---|
| Provoked by transient risk factors (infection, pregnancy, oral contraceptives, minor head trauma) | 3-6 months |
| Unprovoked CVST or mild thrombophilia | 6-12 months with reassessment |
| Severe thrombophilia, antiphospholipid syndrome, or recurrent CVST | Lifelong therapy |
Special Consideration: Antiphospholipid Syndrome
Vitamin K antagonist therapy (target INR ≈ 2.5) is preferred over DOACs for CVST associated with antiphospholipid syndrome. 1
- VKA initiation requires overlapping parenteral anticoagulation until therapeutic INR is achieved 1
Supportive and Symptomatic Management
All patients require: 4
- Seizure management with antiepileptic drugs if early seizures occur, particularly with supratentorial lesions 2
- Intracranial pressure management when elevated
- Prevention of complications through standard supportive care 4
Management of Neurological Deterioration
Endovascular Intervention
Catheter-directed thrombolysis with or without mechanical thrombectomy should be considered when neurological status worsens despite adequate anticoagulation. 1
- This applies to patients who deteriorate despite therapeutic anticoagulation and after other causes of deterioration have been excluded 2, 3
- Recent meta-analysis shows 79% of patients achieve good clinical outcomes (mRS 0-2) with endovascular treatment 5
- Aspiration thrombectomy alone yielded significantly higher rates of good outcomes (83.8%) compared to combined techniques 5
Surgical Decompression
Decompressive hemicraniectomy should be performed in patients with severe mass effect or impending brain herniation to prevent death. 4, 1
- This is a lifesaving procedure for patients with parenchymal lesions causing brain displacement 4
- Two-thirds of patients who undergo decompressive craniectomy survive, with one-third achieving functional independence at 6 months 6
- Consider when there is severe mass effect or intracranial hemorrhage on repeated imaging despite medical treatment 4
Monitoring and Follow-Up
- Functional outcome should be evaluated at 90 days and again at 6 months after the index event 1
- Partial venous recanalization often occurs as early as 8 days after treatment onset with anticoagulation alone 6
Special Populations
Women with Previous CVST
Contraceptives containing estrogens should be avoided in women who have suffered previous CVST. 2
- Subsequent pregnancies are safe, but prophylactic LMWH should be considered throughout pregnancy and puerperium 2, 7
- Women with previous CVST should receive LMWH prophylaxis during pregnancy and for at least 6 weeks postpartum 7
SARS-CoV-2 Vaccine-Associated CVST
- CVST occurring in the first weeks after SARS-CoV-2 vaccination with vector vaccines may be associated with severe thrombocytopenia, indicating vaccine-induced immune thrombotic thrombocytopenia (VITT) 7
Diagnostic Considerations
CT venography or MR venography is recommended for initial imaging in patients with suspected CVST. 4
- Plain CT or MRI should be performed first; if negative but clinical suspicion remains high, proceed to CT venography or MR venography 4
- Catheter angiography may be needed in select cases 4
- D-dimer testing to rule out CVST cannot be recommended and should not be routinely performed 7
- Thrombophilia screening is not generally recommended unless the patient is young, has spontaneous CVST, recurrent thrombosis, positive family history, or if results would change management 7